Literature DB >> 12069994

Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats.

Martin G Ottolini1, Spencer J Curtis, David D Porter, Amy Mathews, Joann Y Richardson, Val G Hemming, Gregory A Prince.   

Abstract

Triamcinolone acetonide, methylprednisolone, and dexamethasone were each evaluated in combination with palivizumab (Synagis) for the therapy of established respiratory syncytial virus infection in the cotton rat. Triamcinolone and methylprednisolone proved to be more effective than dexamethasone in reducing lung pathology. No recurrence of viral replication or pulmonary pathology followed the cessation of therapy.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12069994      PMCID： PMC127305          DOI： 10.1128/AAC.46.7.2299-2302.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.

Authors:  W J Rodriguez; W C Gruber; R C Welliver; J R Groothuis; E A Simoes; H C Meissner; V G Hemming; C B Hall; M L Lepow; A J Rosas; C Robertsen; A A Kramer
Journal:  Pediatrics       Date:  1997-03       Impact factor: 7.124

2.  A prospective randomized double-blind study to evaluate the effect of dexamethasone in acute laryngotracheitis.

Authors:  D M Super; N A Cartelli; L J Brooks; R M Lembo; M L Kumar
Journal:  J Pediatr       Date:  1989-08       Impact factor: 4.406

3.  Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children.

Authors:  W J Rodriguez; W C Gruber; J R Groothuis; E A Simoes; A J Rosas; M Lepow; A Kramer; V Hemming
Journal:  Pediatrics       Date:  1997-12       Impact factor: 7.124

4.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

5.  Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group.

Authors: 
Journal:  Pediatrics       Date:  1997-01       Impact factor: 7.124

Review 6.  Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery.

Authors:  M G Ottolini; V G Hemming
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

7.  Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat.

Authors:  G A Prince; V G Hemming; R L Horswood; R M Chanock
Journal:  Virus Res       Date:  1985-10       Impact factor: 3.303

8.  The pathogenesis of respiratory syncytial virus infection in cotton rats.

Authors:  G A Prince; A B Jenson; R L Horswood; E Camargo; R M Chanock
Journal:  Am J Pathol       Date:  1978-12       Impact factor: 4.307

9.  Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

Authors:  J R Groothuis; E A Simoes; M J Levin; C B Hall; C E Long; W J Rodriguez; J Arrobio; H C Meissner; D R Fulton; R C Welliver
Journal:  N Engl J Med       Date:  1993-11-18       Impact factor: 91.245

10.  Steroid treatment of laryngotracheitis: a meta-analysis of the evidence from randomized trials.

Authors:  S W Kairys; E M Olmstead; G T O'Connor
Journal:  Pediatrics       Date:  1989-05       Impact factor: 7.124
  10 in total
  11 in total

1.  Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency.

Authors:  Asunción Mejías; Susana Chávez-Bueno; Ana María Ríos; Mónica Fonseca Aten; Brett Raynor; Estrella Peromingo; Perla Soni; Kurt D Olsen; Peter A Kiener; Ana María Gómez; Hasan S Jafri; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

2.  The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies.

Authors:  Kevin C Yim; Clifford J Carroll; Ana Tuyama; Natalia Cheshenko; Maria Josefina Carlucci; David D Porter; Gregory A Prince; Betsy C Herold
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Kelsey A Gaston; Sean O Todd; Cemil Boyoglu; Tatiana Chirkova; Thomas R Barnum; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2013-07-24       Impact factor: 5.103

4.  An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Sean O Todd; Tatiana Chirkova; Thomas R Barnum; Kelsey A Gaston; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  Virology       Date:  2015-05-15       Impact factor: 3.616

5.  Respiratory syncytial virus replication is prolonged by a concomitant allergic response.

Authors:  A Hassantoufighi; M Oglesbee; B W M Richter; G A Prince; V Hemming; S Niewiesk; M C Eichelberger
Journal:  Clin Exp Immunol       Date:  2007-03-05       Impact factor: 4.330

6.  Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model.

Authors:  Asunción Mejías; Susana Chávez-Bueno; Ana María Ríos; Jesús Saavedra-Lozano; Mónica Fonseca Aten; Jeanine Hatfield; Payal Kapur; Ana María Gómez; Hasan S Jafri; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  Altered pathogenesis of porcine respiratory coronavirus in pigs due to immunosuppressive effects of dexamethasone: implications for corticosteroid use in treatment of severe acute respiratory syndrome coronavirus.

Authors:  Kwonil Jung; Konstantin P Alekseev; Xinsheng Zhang; Doo-Sung Cheon; Anastasia N Vlasova; Linda J Saif
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

8.  Qing-Wen-Jie-Re Mixture Ameliorates Poly (I:C)-Induced Viral Pneumonia Through Regulating the Inflammatory Response and Serum Metabolism.

Authors:  Qin Li; Tingrui Zhang; Yuming Wang; Shangsong Yang; Junyu Luo; Fang Fang; Jiabao Liao; Weibo Wen; Huantian Cui; Hongcai Shang
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

9.  Pro/con clinical debate: steroids are a key component in the treatment of SARS. Pro: Yes, steroids are a key component of the treatment regimen for SARS.

Authors:  Charles D Gomersall
Journal:  Crit Care       Date:  2004-01-26       Impact factor: 9.097

10.  Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus.

Authors:  M Boukhvalova; J C G Blanco; A R Falsey; J Mond
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.